סך נכסי הפעילות העסקית Synaptogenix Inc. (SNPX)

Synaptogenix, Inc. (SNPX) is building a closed-loop Alzheimer's treatment system via Briostatin-1, tying medical centers to its own protocols. This daily price chart of total assets on GURU.Markets, with a value of 0.00, confirms the potential for monopoly control over the cost of synapse regeneration. The biotech firm is currently revising its research program, focusing on targeted verification of its molecules' performance following the first controversial trials.

For the micro-cap biotech Synaptogenix, Inc. (SNPX), which is focused on a single clinical asset, the aggregate value of resources determines the scale of the operational base. The ROA asset trajectory, calculated inversely through profitability, demonstrates the balance sheet's dependence on the cost of borrowed capital, allowing the investor to assess the risk of over-leverage given management's limited capacity for value creation.